Singapore, Aug. 25 -- Expecto Health Science, an emerging Asia-Pacific Contract Research Organisation (CRO) led by a highly experienced leadership team, announced a strategic collaboration with VertisPro, a leader in AI-driven patient acquisition solutions.

Expecto is known for its strengths in regulatory strategy, clinical trial planning and management across oncology, infectious diseases, medical devices, and cosmetic research. However, patient recruitment particularly in rare disease and oncology trial remains one of the most significant challenges facing sponsors in the region.

Through this partnership, Expecto will integrate VertisPro's advanced AI recruitment solution into its service offering, enabling sponsors to:

"The best col...